QianfoshanH
Jinan, Shandong, 250014, China
NCT Number: NCT06497023
To develop and compare multi-modality radiomics models based on DCE-MRI, B-mode ultrasound (BMUS) and strain elastography (SE) images for classifying benign and malignant breast lesions.
Looking for future studies?
Notify Me15 year–80 year
Female
Observational
Jinan, Shandong, 250014, China
In this retrospective study,555 breast lesions from 555 patients who underwent DCE-MRI, BMUS and SE examinations were randomly divided into training (n =388) and testing (n = 167) datasets. Radiomics features were extracted from manually contoured images. The inter-class correlation coefficient (ICC), Mann-Whitney U test and the least absolute shrinkage and selection operator (LASSO) regression was applied for feature selection and radiomics signature building.Nine radiomics models including four single-modality radiomics models (DCE-3D, DCE-2D, BMUS, and SE), four multi-modality radiomics models (BMUS + SE, DCE-3D + BMUS, DCE-3D + SE, and DCE-3D+SE+BMUS), and the combination diagnostic model(clinical features and DCE-3D+SE+BMUS features) were developed and evaluated by their discrimination, calibration, and clinical usefulness.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients with breast lesions underwent biopsy or surgical resection between January 1, 2018 and March 30, 2024.
Exclusion criteria
Time frame: Immediately evaluated after the radiomcis diagnostic model was built
The accuracy of nine diagnostic models, including four single-modality radiomics models (DCE-3D, DCE-2D, BMUS, and SE), four multi-modality radiomics models (BMUS + SE, DCE-3D + BMUS, DCE-3D + SE, and DCE-3D+SE+BMUS),and the combination diagnostic model is the ratio of the sum of True Positive and True Negative to the total of True Positive, True Negative, False Positive, and False Negative.
Time frame: Immediately evaluated after the radiomcis diagnostic model was built
The sensitivity of nine diagnostic models, four single-modality radiomics models (DCE-3D, DCE-2D, BMUS, and SE), including four multi-modality radiomics models (BMUS + SE, DCE-3D + BMUS, DCE-3D + SE, and DCE-3D+SE+BMUS), and the combination diagnostic model is the ratio of True Positive to the sum of True Positive and False Negative.
Time frame: immediately evaluated after the combination diagnostic model was built
The specificity of nine different diagnostic models, including four single-modality radiomics models (DCE-3D, DCE-2D, BMUS, and SE), four multi-modality radiomics models (BMUS + SE, DCE-3D + BMUS, DCE-3D + SE, and DCE-3D+SE+BMUS), and the combination diagnostic model is the ratio of True Negative to the sum of True Negative and False Positive.
Time frame: immediately evaluated after the combination diagnostic model was built
The PPV of nine different diagnostic models, including four single-modality radiomics models (DCE-3D, DCE-2D, BMUS, and SE), four multi-modality radiomics models (BMUS + SE, DCE-3D + BMUS, DCE-3D + SE, and DCE-3D+SE+BMUS),and the combination diagnostic model is the ratio of True Positive to the sum of True Positive and False Positive.
Time frame: immediately evaluated after the combination diagnostic model was built
The NPV of nine different diagnostic models, including four single-modality radiomics models (DCE-3D, DCE-2D, BMUS, and SE), four multi-modality radiomics models (BMUS + SE, DCE-3D + BMUS, DCE-3D + SE, and DCE-3D+SE+BMUS), and the combination diagnostic model is the ratio of True Negative to the sum of True Negative and False Negative.
Ma Zhe
Other
Multi-modality Radiomics Diagnostic Model Based on DCE-MRI and Ultrasound Images for Benign and Malignant Breast Lesion Classification
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05533099
Breast Diseases, Skin Diseases
Pisa, Italy
View Trial DetailsNCT03709446
Breast Diseases, Breast Neoplasms
New York, United States
View Trial DetailsNCT03730051
Breast Diseases, Skin Diseases
Worcester, Massachusetts, United States
View Trial DetailsNCT06187350
Artificial Intelligence, Breast Diseases
Linköping, Östergötland County, Sweden
View Trial Details